- Home
- REGN vs PBR Comparison
REGN vs PBR Comparison
Compare REGN & PBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- PBR
- Stock Information
- Founded
- REGN 1988
- PBR 1953
- Country
- REGN United States
- PBR Brazil
- Employees
- REGN N/A
- PBR N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- PBR Oil & Gas Production
- Sector
- REGN Health Care
- PBR Energy
- Exchange
- REGN Nasdaq
- PBR Nasdaq
- Market Cap
- REGN 110.0B
- PBR 90.4B
- IPO Year
- REGN 1991
- PBR N/A
- Fundamental
- Price
- REGN $700.33
- PBR $14.78
- Analyst Decision
- REGN Buy
- PBR Strong Buy
- Analyst Count
- REGN 26
- PBR 8
- Target Price
- REGN $996.00
- PBR $18.28
- AVG Volume (30 Days)
- REGN 905.6K
- PBR 13.4M
- Earning Date
- REGN 02-04-2025
- PBR 02-26-2025
- Dividend Yield
- REGN 0.13%
- PBR 16.73%
- EPS Growth
- REGN 10.27
- PBR N/A
- EPS
- REGN 38.34
- PBR 1.20
- Revenue
- REGN $14,202,000,000.00
- PBR $92,525,343,651.00
- Revenue This Year
- REGN $5.20
- PBR $1.14
- Revenue Next Year
- REGN $6.39
- PBR $0.68
- P/E Ratio
- REGN $18.27
- PBR $5.93
- Revenue Growth
- REGN 8.27
- PBR N/A
- 52 Week Low
- REGN $642.00
- PBR $12.55
- 52 Week High
- REGN $1,211.20
- PBR $17.91
- Technical
- Relative Strength Index (RSI)
- REGN 52.55
- PBR 65.63
- Support Level
- REGN $655.85
- PBR $13.49
- Resistance Level
- REGN $689.95
- PBR $14.00
- Average True Range (ATR)
- REGN 21.25
- PBR 0.25
- MACD
- REGN 2.98
- PBR 0.09
- Stochastic Oscillator
- REGN 63.22
- PBR 86.58
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
About PBR Petroleo Brasileiro S.A.- Petrobras
Petrobras is a Brazil-based integrated energy company controlled by the Brazilian government. The company focuses on exploration and production of oil and gas in Brazilian offshore fields. Production in 2023 was 2.8 million barrels of oil equivalent a day (80% oil production), and reserves stood at 10.9 billion boe (85% oil). At end-2023, Petrobras operated 10 refineries in Brazil with capacity of 1.8 million barrels a day and distributes refined products and natural gas throughout Brazil.